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Introduction: Since the first description of Takotsubo cardiomyopathy (TC), an increasing number of cases have been diagnosed and yet there is 
no known effective therapy. More precisely, Beta Blockers (BB) that have been shown to have significant benefit in heart failure have not been shown 
to be of benefit in this disorder when studied in 3 case series. Given TC occurs due to catecholamine surge, we performed a retrospective study of TC 
patients and evaluated the use of BB in this patient population.
Methods: Retrospective study of TC patients seen in a single center between 2003-2010. Inclusion criteria are: TC diagnosis by non-obstructive 
coronary disease on cardiac catheterization, apical ballooning with preserved base of the heart and resolution of cardiomyopathy within 4 weeks by 
echocardiography. Atypical TC presentations on imaging and known obstructive coronary disease are excluded.
Results: 52 patients were selected with mean age 65.9, 83% females with 23% pre-menopausal and youngest is 31 years old. Out of 52, 40% 
Caucasians, 33% Hispanics, 15% African Americans, and 19% others. 66% and 25% of patients have known HTN and DM respectively. Presenting 
symptoms were divided in 3 groups. Group A (n=8, 15 %) have mental stress in form of anxiety, Group B (n=20, 38 %) have chest pain mimicking 
ACS and no anxiety; and Group C (n=24, 47 %) have other medical problems (seizures, post operative, post chemotherapy, acute asthma / COPD). 
Mean EF at the presentation is 36.4 % and at TC resolution is 59.2 %. At presentation, 25% were on BB and 90% were discharged on BB. Cardiogenic 
shock was presenting symptoms in 3 patients and they were treated with BB. None of the patient in our registry died.
Conclusion: TC has varied age groups, predominantly female and post menopausal. Our series is the first to report 17% incidence in males. Only 
15% of patient had anxiety as a stressor. 38% patients have symptoms of ACS making it difficult to differentiate TC from ACS. Only 25% patients were 
on BB before TC onset, which may suggest being BB naïve might be a potential risk factor for TC. Most of our patients tolerated BB after TC and did 
well despite having cardiogenic shock suggesting possible therapeutic benefit of BB.
